Literature DB >> 2110976

Vasoactive intestinal peptide (VIP) as transmitter of inhibitory motor neurons of the gut: evidence from the use of selective VIP antagonists and VIP antiserum.

J R Grider1, J R Rivier.   

Abstract

The role of vasoactive intestinal peptide (VIP) in neurally mediated relaxation of guinea pig and rat intestine was examined with three putative VIP antagonists: a C-terminal sequence of VIP (VIP10-28), substituted analogs of VIP ([4-Cl-D-Phe6, Leu17]VIP) and growth hormone releasing factor (GRF) ([Ac-Tyr1, D-Phe2] GRF1-29). The three agents inhibited selectively relaxation induced by VIP and its homolog, peptide histidine isoleucine. Inhibition of VIP-induced relaxation in tenia coli and gastric fundic strips was consistent with competitive antagonism. Relaxation induced by field stimulation (80 V; 1 msec; 0.1-16 Hz) which is accompanied by a stoichiometric increase in VIP release was inhibited by the three antagonists in the following order of potency: VIP10-28 greater than VIP analog greater than GRF analog. The descending relaxation component of the peristaltic reflex induced by graded stretch of the orad end of a rat colonic segment which is also accompanied by an increase in VIP release, was inhibited by the three VIP antagonists in the same order of potency: VIP10-28 greater than VIP analog greater than GRF analog. The most potent antagonist, VIP10-28, abolished descending relaxation at the lowest grades of stretch (2 and 4 g) and inhibited relaxation at the highest grades of stretch (10 g) by 79%. The results indicate that VIP (and peptide histidine isoleucine) is the transmitter responsible for neurally induced gastric and intestinal relaxation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2110976

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  22 in total

Review 1.  How tolerogenic dendritic cells induce regulatory T cells.

Authors:  Roberto A Maldonado; Ulrich H von Andrian
Journal:  Adv Immunol       Date:  2010       Impact factor: 3.543

2.  Identification of expression and function of the glucagon-like peptide-1 receptor in colonic smooth muscle.

Authors:  Alexander T May; Molly S Crowe; Bryan A Blakeney; Sunila Mahavadi; Hongxia Wang; John R Grider; Karnam S Murthy
Journal:  Peptides       Date:  2018-11-30       Impact factor: 3.750

3.  VIP- and PACAP-mediated nonadrenergic, noncholinergic inhibition in longitudinal muscle of rat distal colon: involvement of activation of charybdotoxin- and apamin-sensitive K+ channels.

Authors:  M Kishi; T Takeuchi; N Suthamnatpong; T Ishii; H Nishio; F Hata; T Takewaki
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

4.  Evidence that nitric oxide acts as an inhibitory neurotransmitter supplying taenia from the guinea-pig caecum.

Authors:  C W Shuttleworth; K M Sweeney; K M Sanders
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

5.  Both ATP and the peptide VIP are inhibitory neurotransmitters in guinea-pig ileum circular muscle.

Authors:  J R Crist; X D He; R K Goyal
Journal:  J Physiol       Date:  1992-02       Impact factor: 5.182

6.  Mediators of nonadrenergic, noncholinergic inhibition in the proximal, middle and distal regions of rat colon.

Authors:  N Suthamnatpong; F Hata; A Kanada; T Takeuchi; O Yagasaki
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

7.  Caveolae-dependent internalization and homologous desensitization of VIP/PACAP receptor, VPAC₂, in gastrointestinal smooth muscle.

Authors:  Sunila Mahavadi; Sayak Bhattacharya; Jennnifer Kim; Sally Fayed; Othman Al-Shboul; John R Grider; Karnam S Murthy
Journal:  Peptides       Date:  2013-03-15       Impact factor: 3.750

8.  Elevated vasoactive intestinal peptide concentrations in patients with irritable bowel syndrome.

Authors:  Olafur S Palsson; Olivier Morteau; Eugene M Bozymski; John T Woosley; R Balfour Sartor; Michael J Davies; David A Johnson; Marsha J Turner; William E Whitehead
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

9.  Evidence for a role for vasoactive intestinal peptide in active vasodilatation in the cutaneous vasculature of humans.

Authors:  Lee Ann T Bennett; John M Johnson; Dan P Stephens; Adham R Saad; Dean L Kellogg
Journal:  J Physiol       Date:  2003-07-07       Impact factor: 5.182

Review 10.  Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease.

Authors:  S G R Smalley; P A Barrow; N Foster
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.